Standard BioTools Inc. Prepaid Expense and Other Assets, Current
Standard BioTools Inc. (LAB) had Prepaid Expense and Other Assets, Current of $7.30 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-08-05
- 2026-06-30: Prepaid Expense and Other Assets, Current $7.30M.
- 2026-03-31: Prepaid Expense and Other Assets, Current $6.05M.
- 2025-12-31: Prepaid Expense and Other Assets, Current $4.87M.
- 2025-09-30: Prepaid Expense and Other Assets, Current $7.91M.
| Period end | Prepaid Expense and Other Assets, Current | Prepaid Expense and Other Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $7.30M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $6.05M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $4.87M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $7.91M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $7.08M 10-Q · filed 2025-08-15 | |
| 2025-03-31 | $8.35M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $4.56M 10-K · filed 2026-03-16 | $8.66M 10-K · filed 2025-03-11 |
| 2024-09-30 | $9.32M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $10.26M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $8.91M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $3.13M 10-K · filed 2025-03-11 | |
| 2023-09-30 | $3.40M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $3.57M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $3.37M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $4.28M 10-K · filed 2024-03-01 | |
| 2022-09-30 | $4.61M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $5.94M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $4.55M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $4.47M 10-K · filed 2023-03-14 | |
| 2021-09-30 | $5.93M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $6.60M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $9.28M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $4.03M 10-K · filed 2022-03-08 | |
| 2020-09-30 | $5.69M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $4.17M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $3.24M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $4.59M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $4.78M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $4.39M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $3.28M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $2.05M 10-K · filed 2020-02-27 | |
| 2018-09-30 | $2.23M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $2.70M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $2.23M 10-Q · filed 2018-05-08 | |
| 2018-01-01 | $1.68M 10-K · filed 2019-03-18 | |
| 2017-12-31 | $1.53M 10-K · filed 2019-03-18 | |
| 2017-09-30 | $2.31M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $4.67M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $1.73M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $2.52M 10-K · filed 2018-03-08 | |
| 2016-09-30 | $3.17M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $3.57M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $3.37M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $5.74M 10-K · filed 2017-03-03 | |
| 2015-09-30 | $2.99M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $2.85M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $1.86M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $2.22M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $3.68M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $3.00M 10-Q · filed 2014-08-04 | |
| 2014-03-31 | $3.45M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $1.54M 10-K · filed 2015-02-26 | |
| 2013-09-30 | $2.54M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $2.04M 10-Q · filed 2013-08-07 | |
| 2013-03-31 | $1.56M 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $1.13M 10-K · filed 2014-03-12 | |
| 2012-09-30 | $1.51M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $1.60M 10-Q · filed 2012-08-14 | |
| 2012-03-31 | $1.57M 10-Q · filed 2012-05-15 | |
| 2011-12-31 | $1.34M 10-K · filed 2013-03-12 | |
| 2011-09-30 | $2.30M 10-Q · filed 2011-11-14 | |
| 2011-06-30 | $1.47M 10-Q · filed 2011-08-09 | |
| 2010-12-31 | $2.17M 10-K · filed 2012-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |